Among patients with recurrence after durvalumab consolidation therapy following CCRT (CCRT–durvalumab), some patients did not achieve sufficient enhancement of anti-tumor immunity with anti-PD-L1 monotherapy. This evidence concerns the gene CD274 and neoplasm.